Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women

Breast Cancer Clinical Trial

Official title:

Multicenter, Randomized Trial to Evaluate Efficacy and Safety of Bevacizumab in Combination With Endocrine Treatment vs Endocrine Alone, in Postmenopausal With Advanced or Metastatic Cancer With Indication of Hormonotherapy as First-line

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00545077
• Other study ID #: GEICAM/2006-11/GBG 51
• Secondary ID: 2007-002841-19
• Status: Completed
• Phase: Phase 3
• Start date: November 6, 2007
• Est. completion date: July 24, 2014

Study information

• Verified date: March 2023
• Source: Spanish Breast Cancer Research Group
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Locally advanced or metastatic breast cancer in postmenopausal women with negative Human Epidermal Growth Factor Receptor 2 (HER2), who are candidates for hormone treatment and who have not received previous chemotherapy or hormonotherapy for the metastatic disease.

Description:

The main endpoint of the study is progression-free survival (PFS). It has been calculated that 378 patients will need to be included, according to the following assumptions:

• Recruitment period of 21 months.

• Minimum follow-up period of 9 months.

• PFS of 9 months in the control arm (letrozole in monotherapy). Using a two-sided log-rank test, for a 5% α level, 344 patients (172 in each treatment arm) will be required for 270 events to occur, which will provide an 80% power for detecting a hazard ratio of 0.69 (corresponding to a PFS median of 13 months in the bevacizumab arm). This sample size has been adjusted for an intermediate analysis when 2/3 of the total of required events have occurred. This intermediate analysis can be avoided if, at the time in which it must be carried out, it is estimated that the final analysis will be carried out in 4 months.

Taking into account a 10% percentage of losses, 378 patients are expected to be included in the study.

An intermediate safety evaluation will be carried out when 63 patients have finished their treatment in each treatment arm.

A multicenter, randomized phase III clinical trial. After verifying the selection criteria, the patients will be randomized to receive letrozole alone or in combination with bevacizumab. Before randomization, the patients will be stratified according to the following prognosis factors:

• Estrogen Receptor (ER)+ / Progesterone Receptor (PgR)+ vs the other options (ER+/PgR- vs ER-/PgR+)

• Previous adjuvant hormonotherapy (yes/no)

• Status: locally advanced vs metastatic.

• Measurable vs non measurable disease

• Visceral disease (yes/no)

• PFS.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 380
• Est. completion date: July 24, 2014
• Est. primary completion date: December 2013
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Before starting the specific protocol procedures, the written informed consent must be obtained and documented.

2. Women = 18 years.

3. Capacity to comply with all the protocol requirements.

4. Functional Eastern Cooperative Oncology Group (ECOG) status of 0 or 1.

5. Life expectancy = 24 weeks.

6. Histologically confirmed breast adenocarcinoma, with measurable or non-measurable, locally advanced or metastatic (stage IV) disease. In the event that the patient only has locally advanced disease, she will not be able to undergo curative local treatment. Patients with metastasis confined to the bone can be chosen, but the disease must be confirmed by radiology, CT scan or Nuclear magnetic resonance (NMR) if there is any doubt after a single bone scan.

7. Patients with HER2-negative disease evaluated by Immunohistochemistry (IHC) and Fluorescence in situ hybridization (FISH)/Chromogenic in situ hybridisation (CISH) (IHC 0 or 1+, or 2+ and negative FISH). Patients with 3+ by IHC cannot be chosen regardless of the FISH/CISH status and those with positive FISH/CISH (> 2 amplifications) cannot be chosen either, regardless of the IHC findings.

8. Positive hormone receptors (estrogen receptor [ER] and/or progesterone receptor [PgR]) evaluated by a local or central laboratory, according to the criteria of the participating institution.

9. Patients who are candidates for receiving first-line treatment with letrozole.

10. Patients may have received (neo)adjuvant chemotherapy, provided that the last dose of the latter was received at least 12 months before randomization. Patients must be recovered from toxicity.

11. The patients are allowed to have received adjuvant radiotherapy, provided that it was completed at least 6 weeks before randomization and the patient has recovered from the reversible acute effects of the radiation. The previous administration of radiotherapy to palliate the pain of bone metastases is authorized, provided that:

• Not more than 30% of bone marrow has been irradiated.

• The patient has recovered from the reversible acute effects of the radiation.

• The patient has at least one metastatic location which has not been irradiated and which may be evaluated for progression, or a clear progression of the bone disease has been objectified after the end of the palliative radiotherapy.

12. The patients may have received any kind of previous (neo)adjuvant hormone therapy provided that they are considered to be candidates for first-line hormonotherapy with either letrozole or fulvestrant.

13. The treatment with bisphosphonates is allowed and recommended for patients with bone metastases. Whenever it is possible, the treatment should be started before or within the 4 weeks of starting the study therapy. The patients starting treatment with bisphosphonates must be carefully evaluated so that they do not mask the progression of the disease.

14. In the patients with heart failure risk (e.g. previously treated with > 360mg/m2 of doxorubicin or equivalent doses of other anthracyclines), the Left Ventricular Ejection Fraction (LVEF) must be determined by means of an echocardiogram or radionuclide ventriculography (MUGA), and it must t be > the lower limit of normal.

Exclusion Criteria:

1. Evolutionary disease requiring an immediate treatment with cytotoxic chemotherapy according to the investigator's judgment.

2. Patients with locally advanced breast cancer who are expected to undergo surgery or curative radiotherapy.

3. Previous chemotherapy or hormonotherapy for the metastatic disease. Patients may have received neoadjuvant chemotherapy or neoadjuvant hormonotherapy with curative intention as a part or as an alternative to an adjuvant treatment. For the previous neoadjuvant hormonotherapy the same premises than for the adjuvant hormonotherapy are valid.

4. Previous therapy with anti-vascular endothelial growth factor (VEGF) or VEGF Receptor (VEGFR) tyrosine-kinase inhibitors.

5. History of another pathology that may affect the development of the protocol or the interpretation of results. It is considered that patients who have suffered from a skin carcinoma that is not melanoma, cervical carcinoma in situ or another neoplasia treated with a curative intention and with a disease-free interval exceeding 5 years can be chosen.

6. Evidence of central nervous system (CNS) metastasis. A CT scan or brain NMR must be done within the 4 weeks before the randomization in case of suspecting brain metastasis.

7. History or evidence in the physical or neurological examination of CNS pathology unrelated to cancer unless it is suitable treated with standard therapy (e.g. uncontrolled convulsions).

8. History of peripheral neuropathy National Cancer Institute (NCI) CTCAE grade >2 at the time of randomization.

9. Patients subjected to major surgical procedures, open biopsies or those having significant trauma injuries within the 28 days prior to randomization, or patients who are expected to undergo a major surgical procedure that must necessarily be performed within the course of the study.

10. Minor surgical procedures in the 7 days prior to randomization.

11. Unsuitable bone marrow supply: absolute neutrophil count (ANC) < 1.5 x 109/L, platelets < 100 x 109/L or Hb < 10 g/dL.

12. Impaired liver function: total bilirubin total > 1.5 x upper limit of normal (ULN), aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) > 2.5 x ULN (> 5 x ULN in patients with liver metastases).

13. Impaired kidney function:

1. Serum creatinine > 2.0 mg/dL or 177 µmol/L.

2. Proteinuria determined by reactive strip > 2+. A 24h determination of proteins in urine will be requested for the patients with > 2+ in the baseline analysis and must have a protein figure < 1 g/24 h.

14. Chronic treatment with oral corticoids (dose > 10 mg/day of methylprednisolone or equivalent): the use of inhaled corticoids is allowed.

15. Chronic treatment with acetylsalicylic acid (> 325 mg/day) or clopidogrel (> 75 mg/day).

16. Uncontrolled arterial hypertension (systolic > 150 mm Hg and/or diastolic > 100 mm Hg) or clinically significant cardiovascular disease: for example cerebrovascular accident (CVA) (in the 6 months prior to randomization), coronaropathy or history of acute mycardial infarction (AMI) in the last 6 months, unstable angina, congestive heart failure of grade > II of the New York Heart Association (NYHA) or severe heart arrhythmias which are not controlled with medication or which can potentially interfere with the study treatment.

17. History or evidence of hemorrhagic diathesis or coagulopathy with bleeding risk.

18. History of abdominal fistula, gastrointestinal perforation or intra-abdominal abcess in the 6 months prior to randomization.

19. Active infection requiring i.v. antibiotics at the time of randomization.

20. Unhealed wounds, active peptic ulcer, esophageal varices.

21. Any other disease, psychological or metabolic alteration, found in the physical or laboratory examination, providing reasonable indications for suspecting a disease or complaint for which the use of any of the study drugs are contraindicated, or which may affect the patient's compliance with the routine procedures of the study or which places the patient at a high risk of experiencing complications related to the treatment.

22. Current or recent (within 30 days prior to that start of the study treatment) treatment with another drug under investigation or participation in another investigation study.

23. Known hypersensitivity to any of the study drugs or their components.

24. Hypersensitivity to the products of Chinese hamster ovary cells or to other human or humanized recombinant antibodies.

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Drug:
• Letrozole

• Bevacizumab

• Fulvestrant

Locations

Country	Name	City	State
Germany	Klinikum Bayreuth	Bayreuth
Germany	Praxis Dr. med. W. Schoenegg	Berlin
Germany	Praxisklinik	Berlin
Germany	Universitätsklinikum Charité	Berlin
Germany	Klinikum Sindelfingen-Böblingen / Kliniken Böblingen	Böblingen
Germany	Johanniter Krankenhaus	Bonn
Germany	Onkologische Schwerpunktpraxis	Bremen
Germany	Berufsausübungsgemeinschaft	Dresden
Germany	Kliniken Essen-Mitte Evang. Huyssens-Stiftung/Knappschaft	Essen
Germany	Universitätsklinikum Essen	Essen
Germany	Kliniken Esslingen	Esslingen
Germany	Klinikum Fulda	Fulda
Germany	Albertinen-Krankenhaus	Hamburg
Germany	Kreiskrankenhaus Hameln	Hameln
Germany	Gynäkologisch-onkologische Praxis	Hannover
Germany	Medizinische Hochschule Hannover	Hannover
Germany	Praxisklinik - Dialysezentrum - Herne	Herne
Germany	St. Vincentius Kliniken Karlsruhe	Karlsruhe
Germany	St. Elisabeth-KKH	Köln
Germany	Onkologische Schwerpunktpraxis	Kronach
Germany	Caritas Krankenhaus Lebach	Lebach
Germany	St. Vincenz Krankenhaus	Limburg
Germany	St. Vincenz und Elisabeth-Hospital	Mainz
Germany	Universitätsklinikum	Mainz
Germany	Ev. Krankenhaus Bethesda	Mönchengladbach
Germany	Universitätsklinikum	Münster
Germany	Frauenklinik Rheinfelden	Rheinfelden
Germany	Klinikum Rosenheim	Rosenheim
Germany	Onkolog. Schwerpunktpraxis	Rosenheim
Germany	Gemeinschaftspraxis für Gynäkologie und Geburtshilfe	Salzgitter
Germany	Krankenhaus Weinheim	Weinheim
Germany	Praxis Dres. Reichert und Janssen	Westerstede
Germany	Dr.-Horst-Schmidt-Kliniken GmbH	Wiesbaden
Germany	St. Josefs-Hospital	Wiesbaden
Germany	Marienhospital Witten	Witten
Germany	Onkologische Gemeinschaftspraxis	Würselen
Spain	Centro Oncológico de Galicia	A Coruña
Spain	Complejo Hospitalario Universitario A Coruña	A Coruña
Spain	Fundación Hospital de Alcorcón	Alcorcón	Madrid
Spain	Hospital General de Alicante	Alicante
Spain	Hospital Infanta Cristina de Badajoz	Badajoz
Spain	Hospital Germans Trias i Pujol	Badalona	Badalona/Barcelona
Spain	Hospital de Barbastro	Barbastro	Huesca
Spain	Hospital Clinic i Provincial	Barcelona
Spain	Hospital del Mar	Barcelona
Spain	Hospital Provincial de Córdoba	Córdoba
Spain	Hospital General de Elche	Elche	Alicante
Spain	Instituto Catalan de Oncologia de Girona	Girona
Spain	Instituto catalán de Oncología de Barcelona	Hospitalet de Llobregat	Barcelona
Spain	Complejo Hospitalario de Jaén	Jaén
Spain	Hospital Universitario de Canarias	La Laguna	Santa Cruz De Tenerife
Spain	Hospital Arnau de Vilanova de Lérida	Lérida
Spain	CIOCC Clara Campal	Madrid
Spain	Hospital Clínico San Carlos	Madrid
Spain	Hospital Gregorio Marañon	MAdrid
Spain	Hospital Ramón y Cajal	Madrid
Spain	Hospital Universitario Virgen de la Victoria	Málaga
Spain	Xarxa Asistencial de Manresa	Manresa	Barcelona
Spain	Hospital Son Dureta	Palma De Mallorca	Islas Baleares
Spain	Corporación Sanitaria Parc Taulí	Sabadell	Barcelona
Spain	Hospital Universitario Virgen del Rocío	Sevilla
Spain	Hospital Virgen de La Macarena	Sevilla
Spain	Consorci Sanitari de Terrasa	Terrassa	Barcelona
Spain	Hospital Mutua de Terrasa	Terrassa	Barcelona
Spain	Hospital Virgen de la Salud	Toledo
Spain	Hospital Clinico de Valencia	Valencia
Spain	Hospital Clinico Universitario Valencia	Valencia
Spain	Hospital Universitario La Fe	Valencia
Spain	Instituto Valenciano de Oncología	Valencia
Spain	Hospital Miguel Servet	Zaragoza

Sponsors (3)

Lead Sponsor	Collaborator
Spanish Breast Cancer Research Group	German Breast Group, Hoffmann-La Roche

Countries where clinical trial is conducted

Germany,  Spain, 

References & Publications (3)

Martin M, Loibl S, Hyslop T, De la Haba-Rodriguez J, Aktas B, Cirrincione CT, Mehta K, Barry WT, Morales S, Carey LA, Garcia-Saenz JA, Partridge A, Martinez-Janez N, Hahn O, Winer E, Guerrero-Zotano A, Hudis C, Casas M, Rodriguez-Martin C, Furlanetto J, C — View Citation

Martin M, Loibl S, von Minckwitz G, Morales S, Martinez N, Guerrero A, Anton A, Aktas B, Schoenegg W, Munoz M, Garcia-Saenz JA, Gil M, Ramos M, Margeli M, Carrasco E, Liedtke C, Wachsmann G, Mehta K, De la Haba-Rodriguez JR. Phase III trial evaluating the — View Citation

Polley MC, Dickler MN, Sinnwell J, Tenner K, de la Haba J, Loibl S, Goetz MP, Bergh J, Roberston J, Couch F, Ellis MJ, Martin M. A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced breast cancer treated with — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression-free Survival (PFS)	PFS was defined as the time elapsed from randomization until the date in which the progression of the disease or the death for any reason (whichever occurs first) is documented.	Up to 2 years
Secondary	Overall Survival (OS)	OS was defined as the time elapsed since randomization, until the time in which death occurs for any reason. The patients lost in the follow-up will be censured at the date of the last follow-up.	Up to 2 years
Secondary	Time to Treatment Failure (TTF)	TTF was defined as the time elapsed since randomization until the date the treatment is discontinued for any reason (progression disease, treatment toxicity or death).	Up to 2 years
Secondary	Overall Response Rate (ORR)	ORR to treatment is reflected by a frequency table containing the data of the best overall response (Complete Response, Partial Response,Stable Disease or Progressive Disease) experienced for each patient during treatment (recorded from the start of the treatment until disease progression) per arm.	2 years
Secondary	Response Duration (RD)	RD was defined as the time elapsed from when a partial or complete response is verified until the time in which progression or death occurs.	Up to 2 years
Secondary	Clinical Benefit Rate (CBR)	CBR was defined as the percentage of patients achieving a Complete Response (CR), a Partial Response (PR) or a stabilization of the disease (SD) > 6 months: the response will be evaluated according to the RECIST criteria. In the patients without measurable disease at the baseline time, the clinical benefit will be defined as the absence of progression > 6 months.	Up to 2 years

External Links

•   Spanish Breast Cancer Research Group (GEICAM) is a Spanish Breast Cancer Research Group